Chinese herbal compound prescriptions combined with Chinese medicine powder based on traditional Chinese medicine syndrome differentiation for treatment of chronic atrophic gastritis with erosion: a multi-center, randomized, positive-controlled clinical trial

被引:22
|
作者
Zhang, Tai [1 ,2 ,3 ]
Zhang, Beihua [1 ,2 ,3 ]
Xu, Jinkang [4 ]
Ren, Shunping [5 ]
Huang, Shaogang [6 ]
Shi, Zhaohong [7 ]
Guo, Shaoju [8 ]
Bian, Liqun [1 ,2 ,3 ]
Wang, Ping [1 ,2 ,3 ]
Wang, Fengyun [1 ,2 ,3 ]
Cai, Yidong [1 ,2 ,3 ]
Tang, Xudong [3 ]
机构
[1] China Acad Chinese Med Sci, Xiyuan Hosp, Beijing, Peoples R China
[2] China Acad Chinese Med Sci, Xiyuan Hosp, Dept Gastroenterol, Beijing, Peoples R China
[3] China Acad Chinese Med Sci, Xiyuan Hosp, Inst Digest Dis, Beijing, Peoples R China
[4] Kunshan Tradit Chinese Med Hosp, Dept Gastroenterol, Kunshan, Peoples R China
[5] Hosp Shanxi Univ Chinese Med, Dept Gastroenterol, Taiyuan, Peoples R China
[6] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Dept Gastroenterol, Guangzhou, Peoples R China
[7] Wuhan 1 Hosp, Dept Gastroenterol, Wuhan, Peoples R China
[8] Guangzhou Univ Chinese Med, Shenzhen Tradit Chinese Med Hosp, Clin Med Coll 4, Dept Gastroenterol, Shenzhen, Peoples R China
关键词
Traditional Chinese medicine; Chronic gastritis with erosion; Multi-center; randomized study; Endoscopy; HELICOBACTER-PYLORI; INTESTINAL METAPLASIA; VERRUCOUS GASTRITIS; ENDOSCOPIC FINDINGS; DOUBLE-BLIND; RISK; ACID; THERAPY;
D O I
10.1186/s13020-022-00692-7
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Background: In this study, Chinese herbal compound prescriptions combined with Chinese medicine powder were evaluated for the treatment of chronic atrophic gastritis with erosion. Methods: This multi-center, randomized, positive drug control clinical trial randomly assigned 216 patients with chronic atrophic gastritis with erosion to three groups: (1) control group: aluminum plus magnesium suspension thrice per day for 4 weeks; (2) test group 1: Chinese herbal compound prescriptions twice a day plus Sanqi (Panax notoginseng) powder twice a day for 4 weeks; (3) test group 2: Chinese herbal compound prescriptions twice a day plus Sanqi (Panax notoginseng) powder and Zhebeimu (Fritillaria thunbergii Miq.) powder twice a day for 4 weeks. The primary endpoint (improvement of gastric mucosal erosion; improvement of gastric mucosal pathology) and secondary endpoints (improvement of clinical symptoms scores; improvement of the patient-reported outcome [PRO] instrument for chronic gastrointestinal diseases) were assessed using endoscopy at week 4 following the treatment. Drug-related adverse events (AEs) and adverse drug reactions (ADRs) were also compared.Results: The final analysis included 202 patients (control group, 63; test group 1, 69; test group 2, 70). At week 4, using within-group comparison, gastric mucosal erosion improved in each group following treatment with a significant difference (P < 0.05); there were no statistically significant differences in gastric mucosal erosion scores among the groups after treatment (P > 0.05); in terms of improvement of gastric mucosal erosion, the efficacy rate of the control group was 69.12%, the efficacy rate of the test group 1 was 73.24%, and the efficacy rate of the test group 2 was 69.01% and efficacy rate among the groups was not statistically significant (P > 0.05). As determined by acute inflammation, chronic inflammation, atrophy, intestinal metaplasia, and dysplasia, the pathological score (total score and the highest score) did not differ statistically among groups following treatment (P > 0.05); within the control group, the total scores of acute inflammation, chronic inflammation, atrophy, and intestinal metaplasia were significantly decreased (P < 0.05), but there was no significant improvement in dysplasia (P > 0.05); in the test group 1, chronic inflammation, atrophy, and intestinal metaplasia and dysplasia scores were significantly decreased (P < 0.05), but acute inflammation did not improve (P > 0.05); there was a significant reduction in the atrophy score in test group 2 (P < 0.05), but no improvement in the scores of acute inflammation, chronic inflammation, intestinal metaplasia, and dysplasia was observed (P > 0.05). Similarly, within the control group, the highest scores of acute inflammation, chronic inflammation, atrophy, and intestinal metaplasia were significantly decreased (P < 0.05), but there was no significant improvement in dysplasia (P > 0.05); there was a significant reduction in highest scores of atrophy, intestinal metaplasia, and dysplasia (P < 0.05) in test group 1, but the highest scores didn't not improve with acute inflammation and chronic inflammation (P > 0.05); there was a significant reduction in the highest atrophy score in test group 2 (P < 0.05), but no improvement in the highest scores of acute inflammation, chronic inflammation, intestinal metaplasia, and dysplasia was observed (P > 0.05). Compared to the control group, the main symptom scores and total symptom scores in the test groups were lower following treatment, with a statistically significant difference (P < 0.05); the analysis of covariance with center, erosion type, and group as factors was applied, and the comparison among the groups in dyspepsia, defecation, and total PRO instrument scores were statistically significant (P < 0.05). In the study period, AEs were reported in 3 (4.23%) patients in the test group 1 and 3 (4.41%) patients in the control group; ADRs were confirmed in 3 (4.23%) patients from the test group 1 and 2 (2.94%) from the control group. AEs and ADRs were not statistically significantly different among groups (AE, P = 0.2213; ADR, P = 0.2872). No serious AE or ADR was reported.Conclusions: This study has shown that both aluminum plus magnesium suspension and Chinese herbal compound prescriptions together with Panax notoginseng powder are capable of improving gastric mucosal erosion and reducing gastric mucosal pathological scores, and there were no statistically significant differences among the groups in primary endpoints, indicating that Chinese herbal therapy can achieve similar efficacy than antacids in terms of primary outcomes. The aluminum plus magnesium suspension is comparable to Chinese herbal therapy in improving atrophy and intestinal metaplasia, and is inferior to Chinese herbal therapy in improving dysplasia. In addition, the Chinese herbal therapy significantly outperforms the aluminum plus magnesium suspension in improving symptoms. Therefore, the overall clinical outcome of Chinese herbal compound prescriptions together with Panax notoginseng powder based on TCM syndrome patterns in the treatment of erosive gastritis is superior to that of antacids. Trial registration ChiCTR, ChiCTR-IPR-15005905. Registered 22 January 2015, https://www.chictr.org.cn/showproj.aspx? proj=10359
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Chinese herbal compound prescriptions combined with Chinese medicine powder based on traditional Chinese medicine syndrome differentiation for treatment of chronic atrophic gastritis with erosion: a multi-center, randomized, positive-controlled clinical trial
    Tai Zhang
    Beihua Zhang
    Jinkang Xu
    Shunping Ren
    Shaogang Huang
    Zhaohong Shi
    Shaoju Guo
    Liqun Bian
    Ping Wang
    Fengyun Wang
    Yidong Cai
    Xudong Tang
    Chinese Medicine, 17
  • [2] Perspectives of international multi-center clinical trials on traditional Chinese herbal medicine
    Wu, Shan
    Wang, Chuanchi
    Bai, Dong
    Chen, Nanjie
    Hu, Jingqing
    Zhang, Junhua
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [3] Effectiveness of Chinese herbal medicine granules and traditional Chinese medicine-based psychotherapy for perimenopausal depression in Chinese women: a randomized controlled trial
    Cao, Xiao-jing
    Huang, Xu-chun
    Wang, Xiaoyun
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2019, 26 (10): : 1193 - 1203
  • [4] Treatment of irritable bowel syndrome with Chinese herbal medicine - A randomized controlled trial
    Bensoussan, A
    Talley, NJ
    Hing, M
    Menzies, R
    Guo, A
    Ngu, M
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (18): : 1585 - 1589
  • [5] Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B:Study Protocol for a Multi-Center,Double-Blind Randomized-Controlled Trial
    YE Yong-an
    LI Xiao-ke
    ZHOU Da-qiao
    CHI Xiao-ling
    LI Qin
    WANG Li
    LU Bing-jiu
    MAO De-wen
    WU Qi-kai
    WANG Xian-bo
    ZHANG Ming-xiang
    XUE Jing-dong
    LI Yong
    LU Wei
    GUO Jian-chun
    JIANG Feng
    ZHANG Xin-wei
    DU Hong-bo
    YANG Xian-zhao
    GUO Hui
    GAN Da-nan
    LI Zhi-guo
    Chinese Journal of Integrative Medicine, 2018, 24 (09) : 653 - 660
  • [6] Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial
    Yong-an Ye
    Xiao-ke Li
    Da-qiao Zhou
    Xiao-ling Chi
    Qin Li
    Li Wang
    Bing-jiu Lu
    De-wen Mao
    Qi-kai Wu
    Xian-bo Wang
    Ming-xiang Zhang
    Jing-dong Xue
    Yong Li
    Wei Lu
    Jian-chun Guo
    Feng Jiang
    Xin-wei Zhang
    Hong-bo Du
    Xian-zhao Yang
    Hui Guo
    Da-nan Gan
    Zhi-guo Li
    Chinese Journal of Integrative Medicine, 2018, 24 : 653 - 660
  • [7] Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B:Study Protocol for a Multi-Center,Double-Blind Randomized-Controlled Trial
    YE Yongan
    LI Xiaoke
    ZHOU Daqiao
    CHI Xiaoling
    LI Qin
    WANG Li
    LU Bingjiu
    MAO Dewen
    WU Qikai
    WANG Xianbo
    ZHANG Mingxiang
    XUE Jingdong
    LI Yong
    LU Wei
    GUO Jianchun
    JIANG Feng
    ZHANG Xinwei
    DU Hongbo
    YANG Xianzhao
    GUO Hui
    GAN Danan
    LI Zhiguo
    Chinese Journal of Integrative Medicine, 2018, (09) : 653 - 660
  • [8] Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial
    Ye Yong-an
    Li Xiao-ke
    Zhou Da-qiao
    Chi Xiao-ling
    Li Qin
    Wang Li
    Lu Bing-jiu
    Mao De-wen
    Wu Qi-kai
    Wang Xian-bo
    Zhang Ming-xiang
    Xue Jing-dong
    Li Yong
    Lu Wei
    Guo Jian-chun
    Jiang Feng
    Zhang Xin-wei
    Du Hong-bo
    Yang Xian-zhao
    Guo Hui
    Gan Da-nan
    Li Zhi-guo
    CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2018, 24 (09) : 653 - 660
  • [9] Clinical study on microscopic syndrome differentiation and traditional Chinese medicine treatment for liver stomach disharmony in chronic gastritis
    Bai, Chun-Yan
    Tian, Wei
    Zhang, Qian
    WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2024, 16 (05):
  • [10] Randomized controlled multicenter clinical trial for integrated treatment of community-acquired pneumonia based on Traditional Chinese Medicine syndrome differentiation
    Li, Jiansheng
    Yu, Xueqing
    Li, Suyun
    Wang, Haifeng
    Bai, Yunping
    Wang, Minghang
    Sun, Zikai
    Zhang, Wei
    Zhou, Zhaoshan
    Jia, Xianhua
    Zhou, Qingwei
    JOURNAL OF TRADITIONAL CHINESE MEDICINE, 2012, 32 (04) : 554 - 560